Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Andrew J. Fratoni"'
Publikováno v:
Journal of Antimicrobial Chemotherapy. 77:2992-2999
Background Imipenem and relebactam are predominantly excreted via glomerular filtration. Augmented renal clearance (ARC) is a common syndrome in critically-ill patients with sepsis, and sub-therapeutic antibiotic concentrations are of concern. Herein
Publikováno v:
Journal of Antimicrobial Chemotherapy. 77:1052-1060
Background Minocycline displays high susceptibility rates against Stenotrophomonas maltophilia at the current breakpoint of 4 mg/L. However, no pharmacodynamic data are available to guide dosing or justify this breakpoint. Methods The murine neutrope
Autor:
Andrew J Fratoni, Angela Berry, Haitao Yuan, Xiao Liu, Xi Chen, Yuchuan Wu, David P Nicolau, Kamilia Abdelraouf
Publikováno v:
Open Forum Infectious Diseases. 9
Background Imipenem (IPM)/XNW4107 is a novel β-lactam/β-lactamase inhibitor with in vitro activity against serine carbapenemase-producing Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacterales. Herein, we evaluated the in vivo activit
Publikováno v:
Open Forum Infectious Diseases. 9
Background Administration of the oral carbapenem, tebipenem along with its broad spectrum of activity against anaerobic, Gram-positive and Gram-negative pathogens including extended-spectrum β-lactamase-producing Enterobacterales, offers clinicians
Autor:
Andrew J Fratoni, Abigail K Kois, Jessica L Colmerauer, Kristin E Linder, David P Nicolau, Joseph L Kuti
Publikováno v:
Open Forum Infectious Diseases. 9
Patients hospitalized with coronavirus disease 2019 (COVID-19) often receive empiric antibiotic coverage. Procalcitonin (PCT) is a biomarker with Food and Drug Administration–approved guidance cutoffs for antibiotic use in lower respiratory tract i
Publikováno v:
The Journal of antimicrobial chemotherapy. 78(1)
Objective Tebipenem pivoxil hydrobromide is a novel oral carbapenem prodrug of tebipenem, the active moiety. We assessed tebipenem steady-state pharmacokinetics in the skin and soft tissue in healthy subjects and infected patients with diabetes using
Publikováno v:
The Journal of antimicrobial chemotherapy. 78(1)
Objectives Oral β-lactam treatment options for MDR Enterobacterales are lacking. Ledaborbactam (formerly VNRX-5236) is a novel orally bioavailable β-lactamase inhibitor that restores ceftibuten activity against Ambler Class A-, C- and D-producing E
Autor:
Andrew J. Fratoni, Jessica L. Colmerauer, Kristin E. Linder, David P. Nicolau, Joseph L. Kuti
Publikováno v:
Journal of pharmacy practice.
Background: A Best Practice Advisory (BPA) warns clinicians of an interaction between carbapenems and valproic acid (VPA) that can cause significant declines in VPA levels leading to serious consequences for patients treated for seizure disorder and
Publikováno v:
The Journal of antimicrobial chemotherapy. 77(5)
Objectives We assessed the plasma and soft-tissue pharmacokinetic exposure of omadacycline in infected patients with diabetic foot infection (DFI) and healthy volunteers using in vivo microdialysis. Methods Eight patients and six healthy volunteers w
Publikováno v:
The Journal of antimicrobial chemotherapy. 77(1)
Background Levofloxacin displays in vitro activity against Stenotrophomonas maltophilia (STM); however, current susceptibility breakpoints are supported by limited data. We employed the murine neutropenic thigh infection model to assess levofloxacin